Background: There is a paucity of prospective studies evaluating the atypical features of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Aims: To compare clinical and electrodiagnostic features of clinically typical and atypical CIDP patients. Methods: The patients with typical and atypical CIDP diagnosed according to the European Federation of Neurological Societies/Peripheral Nerve Society were included. The disability was graded on a 0–10 scale. Neurophysiological study included motor and sensory nerve conduction and F wave studies of both upper and lower limbs. The patients were treated with prednisolone with or without azathioprine. The outcome was evaluated at 6 months and improvement was defined as at least 2 grades improvement. Results: Eight out of 37 CIDP patients had atypical features, which included asymmetry in 2, dysautonomia in 3 and pure motor weakness, amyotrophic-lateral-sclerosis-like syndrome and distal weakness in 1 patient each. Tendon reflexes were retained in 3 patients. The mean duration of symptoms was 43 weeks in the typical and 30 weeks in the atypical group. The age, sex, disability, therapeutic response and neurophysiological features were similar in the 2 groups. Conclusion: About one fifth of CIDP patients may have atypical clinical features; however, their electrodiagnostic features and response to treatment are no different from typical CIDP.

1.
Joint Task Force of the EFNS and the PNS: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2005;10:220–228.
2.
Oh SJ, Joy JL, Kurnoglu R: ‘Chronic sensory demyelinating neuropathy’: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry 1992;55:677–680.
3.
Gorson KC, Allam G, Ropper AH: Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321–328.
4.
Rotta FT, Sussman AT, Bradley WG, Ayyar DR, Sharma KR, Shebert RT: The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000;173:129–139.
5.
Cros D, Chiappa KH, Patel S, Gominak S: Acquired pure sensory demyelinating polyneuropathy: a chronic inflammatory demyelinating polyradiculoneuropathy variant? Ann Neurol 1992;32:280.
6.
Sasaki M, Ohara S, Oide T, Hayashida K, Hayashi R: An autopsy case of chronic inflammatory demyelinating polyradiculoneuropathy with respiratory failure. Muscle Nerve 2004;30:382–387.
7.
Yamamoto K, Watarai M, Hashimoto T, Ikeda SI: Chronic inflammatory demyelinating polyradiculoneuropathy with autonomic involvement. Muscle Nerve 2005;31:108–112.
8.
Ginsberg L, Platts AD, Thomas PK: Chronic inflammatory demyelianting polyneuropathy mimicking a lumbar spinal stenosis syndrome. J Neurol Neurosurg Psychiatry 1995;59:189–191.
9.
Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double blind, sham controlled, cross over study. Brain 1996;119:1055–1066.
10.
Kalita J, Misra UK: Postural hypotension in a patient with acute myelitis. Postgrad Med J 1996;72:180–182.
11.
Misra UK, Kalita J: Clinical Neurophysiology: Nerve Conduction-Electromyography-Evoked Potential. New Delhi, Elsevier, 2003.
12.
Ad Hoc Subcommittee of American Academy of Neurology AIDS Task Force: Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1991;41:617–618.
13.
Nicolas G, Massonobe T, Forestier NLE, et al: Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002;25:26–30.
14.
Verma A, Tandan R, Adesina AM, Pendlebury WW, Fries TJ, Bradley WG: Focal neuropathy preceding chronic inflammatory demyelinating polyradiculopathy by several years. Acta Neurol Scand 1990;81:516–521.
15.
Vanden Berg-Vos RM, Van den Berg LH, Franssen H, et al: Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity. Neurology 2000;54:26–32.
16.
Vallat JM, Tabaraud F, Magy L, et al: Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases. Muscle Nerve 2003;27:478–485.
17.
Kuwabara S, Ogawara K, Koga M, Mori M, Hattori T, Yuki N: Hyperreflexia in Guillain-Barré syndrome: relation with acute motor axonal neuropathy and anti-GM1 antibody. J Neurol Neurosurg Psychiatry 1999;67:180–184.
18.
Kalita J, Misra UK, Bansal R: Central motor conduction studies in patients with Guillain-Barré syndrome. Electromyogr Clin Neurophysiol 2001;41:243–246.
19.
Oh SJ, Birmingham AL: ‘Amyotrophic lateral sclerosis form’ of chronic inflammatory demyelinating polyneuropathy. Ann Neurol 1990;28:269.
20.
Chiang MC, Lin YH, Pan CL, Tseng TJ, Lin WM, Hsieh ST: Cutaneous innervation in chronic inflammatory demyelinating polyneuropathy. Neurology 2002;59:1094–1098.
21.
Ingall TJ, McLeod JG, Tamura N: Autonomic function and unmyelinated fibers in chronic inflammatory demyelinating polyradiculoenuropathy. Muscle Nerve 1990;13:70–76.
22.
Gorson KC, Ropper AH, Adelman LS, Weinberg DH: Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2000;23:37–43.
23.
Stewart JD, McKelvey R, Liam Durcan L, Carpenter S, Karpati G: Chronic inflammatory demyelianting polyneuropathy (CIDP) in diabetics. J Neurol Sci 1996;142:59–64.
24.
Uncini A, De Angelis MV, Di Muzio A, Callegarini C, Ciucci G, Antonini G, Lugaresi A, Gambi D: Chronic inflammatory demyelinating polyneuropathy in diabetics: motor conductions are important in the differential diagnosis with diabetic polyneuropathy. Clin Neurophysiol 1999;110:705–711.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.